前列腺癌分子生物学:当前理解与临床意义
本文综述前列腺癌分子生物学研究进展,涵盖染色体改变、AR突变、遗传与体细胞突变、SNP及免疫治疗等。染色体区域扩增或缺失导致拷贝数与基因表达变化,部分遗传部分体细胞突变。去势抵抗性前列腺癌研究揭示AR表达增强、扩增、点突变及可变剪接等突变类型。
要点
- 染色体反复改变导致区域扩增(功能获得)或缺失(功能丧失),引起拷贝数与基因表达变异。
- 部分染色体改变为遗传性,部分为疾病进展中的体细胞突变。
- 去势抵抗性前列腺癌中AR自身突变包括表达增强与扩增、点突变及可变剪接。
核心结论
- 前列腺癌是与年龄相关的疾病,随着预期寿命增加需重视;针对肿瘤独特分子谱的靶向治疗是战胜该病的最佳方式。
研究设计与样本
- 综述类:使用MEDLINE®和Google Scholar进行全面文献检索,关键词涉及前列腺癌遗传学如染色体改变、雄激素受体、去势抵抗、遗传、多态性、癌基因、转移、生物标志物和免疫治疗。
主要发现
- 染色体反复改变导致区域扩增(功能获得)或缺失(功能丧失),引起拷贝数与基因表达变异。
- 部分染色体改变为遗传性,部分为疾病进展中的体细胞突变。
- 家族连锁研究已鉴定出使人易感前列腺癌的遗传基因突变;也鉴定出促进肿瘤发生的体细胞基因。
- 分子生物学研究将这些基因分类为抑癌基因或癌基因;全基因组研究鉴定出众多高风险SNP反复出现。
- 去势抵抗性前列腺癌是最具侵袭性的形式,研究揭示AR自身多种突变包括表达增强与扩增、点突变及可变剪接。
临床怎么用
- 对前列腺癌分子生物学的理解允许使用先进生物标志物进行更准确识别,并对侵袭性形式使用免疫治疗。
- 针对肿瘤独特分子谱设计的靶向治疗被认为是战胜前列腺癌的最佳方式。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With continuous progress over the past few decades in understanding diagnosis, treatment, and genetics, much has been learned about the prostate cancer-diagnosed genome. METHODS: A comprehensive MEDLINE® and Google scholar literature search was conducted using keyword variations relating to the genetics of prostate cancer such as chromosomal alterations, androgen receptor, castration-resistant, inheritance, polymorphisms, oncogenes, metastasis, biomarkers, and immunotherapy. RESULTS: Traditionally, androgen receptors (AR) have been the focus of research. Recently, identification of recurrent chromosomal alterations that lead to either multiplication of regions (gain-of-function) or deletion of regions (loss-of-function) has opened the door to greater genetic accessibility. These chromosomal aberrations lead to variation in copy number and gene expression. Some of these chromosomal alterations are inherited, while others undergo somatic mutations during disease progression. Inherited gene mutations that make one susceptible to prostate cancer have been identified with familial-linked studies. Somatic genes that progress tumorigenesis have also been identified. Research on the molecular biology of prostate cancer has characterized these genes into tumor suppressor genes or oncogenes. Additionally, genome-wide assay studies have identified many high-risk single-nucleotide polymorphisms recurrent throughout the prostate cancer-diagnosed genome. Castration-resistant prostate cancer is the most aggressive form of prostate cancer, and its research has elucidated many types of mutations associated with AR itself, including enhanced expression and amplification, point mutations, and alternative splicing. Understanding the molecular biology of prostate cancer has permitted more accurate identification using advanced biomarkers and therapy for aggressive forms using immunotherapy. CONCLUSIONS: An age-related disease, prostate cancer commands profound attention. With increasing life expectancy and the continuous pursuit of it, prostate cancer is a powerful obstacle best defeated using targeted therapies specifically designed for the unique molecular profile of the malignancy.
引用
- Gandhi J, Afridi A, Vatsia S, et al. The molecular biology of prostate cancer: current understanding and clinical implications. Prostate Cancer Prostatic Dis. 2017. PMID: 29282359. doi:10.1038/s41391-017-0023-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。